Summary
Six patients have been treated with 131I labelled anti-tenascin (IgG2A) Mab. Administration directly into the solid component of the tumour was achieved via either one or two stereotactically placed catheters. Up to 600 MBq of MAb conjugated 131I was infused at a rate of 50-100 µl/hour. Throughout therapy, urine collection, blood sampling, whole body activity measurements, whole body scans and SPECT scans of the tumour were carried out regularly. Absorbed doses to the bladder, blood, whole body and tumour were calculated according to the MIRD system.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bloom H.J.G. Intra-cranial tumours; Response and resistance to therapeutic endeavours 1970–1980 (4th Juan A. Del Regato Lecture 1980 ) Int J Radiation Oncol Biol Phys 1982; 8: 1083–1113.
Walker M.D, Strike T.A, Sheline G.E. Analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5: 1925.
Zalutsky M, Moseley P, Bigner D, et al. Pharmacokinetics and tumour localisation of 131 labelled anti-tenascin monoclonal antibody 8106 in patients with Glioma and other intracranial malignancies. Cancer Research 1989; 49: 2807–2813.
Riva R, Arista A, Sturiale C, et al. Treatment of intracranial human Glioblastoma by direct intralesional administration of I-131 labelled anti-tenascin Mab BC-2. Int J Cancer 1993; 51: 7–13.
Fraker P.J, Speck J.C. Protein and Cell Membrane Iodinations with a Sparingly Soluble Chloroamide, 1,3,4,6-Tetrachloro-3a,6a-Diphenylglycoluril. Biochem Biophys Res Comm 1984; 80: 849–857.
Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn P.A. Determination of the Immunoreactive Fraction of Radiolabeled Monoclonal-Antibodies by Linear Extrapolation to Binding at Infinite Antigen Excess. J Immunol Methods 1984; 72: 77–89.
Loevinger R, Budinger T.F, Watson E.E. In: Loevinger R, Budinger T.F, Watson E.E in collaboration with Medical International Radiation Dose (MIRD) committee (eds) MIRD primer for absorbed dose calculations. Society of Nuclear Medicine, New York 1989.
Fielding S.L, Flower M.A, Ackery D, Kemshead J.T, Lashford L.S, Lewis I. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nuc Med 1991; 18: 308–316.
Snyder W.S, Ford M.R, Warner G.G, et al. “S”, Absorbed Dose Per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD Pamphlet No. 11. New York: The Society of Nuclear Medicine, 1975.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Birkhäuser Verlag Basel
About this chapter
Cite this chapter
Chittenden, S. et al. (1995). Dosimetry of Intralesional 131I-Monoclonal Antibody (MAb) Therapy in Patients with Recurrent High Grade Gliomas. In: Bergmann, H., Sinzinger, H. (eds) Radioactive Isotopes in Clinical Medicine and Research. Advances in Pharmacological Sciences. Birkhäuser Basel. https://doi.org/10.1007/978-3-0348-7340-6_5
Download citation
DOI: https://doi.org/10.1007/978-3-0348-7340-6_5
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-0348-7342-0
Online ISBN: 978-3-0348-7340-6
eBook Packages: Springer Book Archive